Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Good news and a catch for RA patients: modern treatments are helping more people reach remission faster than in the 1990s, but relapse rates after remission have also climbed. A large population-based study found median time to remission dropped from 6.4 years to 2.8 years over three decades. The challenge now is keeping patients in remission once they get there.
Modern RA care is winning the battle for remission — but struggling to hold the line.
A retrospective study of nearly 1,200 rheumatoid arthritis (RA) patients in Minnesota spanning three decades found that patients diagnosed in the 2010s achieved remission at significantly higher rates and in roughly half the time compared to those diagnosed in the 1990s. The widespread adoption of conventional and biologic disease-modifying antirheumatic drugs (DMARDs) is credited as a key driver of this improvement.
But there's a catch: relapse rates after first remission have also risen sharply. More than 80% of patients who achieved remission in the 2000s relapsed within 5 years, compared to about 63% in the 1990s — suggesting that while modern therapies are better at inducing remission, sustaining it remains an unresolved challenge.
By the Numbers:
Why it matters: As RA therapies grow more powerful at achieving remission, the field must now focus on durability — identifying who is at risk of relapse and optimizing when to escalate or taper treatment.
